MONTREAL (CANADA) – January 10, 2022 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Karine Lalonde, MSc as Vice-President, Clinical Operations, effective immediately. With 20 years of experience in clinical research operations, she brings to Inversago’s drug development program proven abilities in seamless clinical trial management, building strong internal cross-functional collaboration and CRO partnerships.
“Karine has demonstrated strong leadership abilities in a fast-paced clinical environment, which are pivotal as the Company ramps up its clinical operations in 2022”, stated Glenn D. Crater, MD, FCCP, CMO of Inversago Pharma.
Prior to joining the leadership team, Karine Lalonde was most recently Senior Director, Clinical Operations, in which role she demonstrated exceptional skills in helping Inversago deliver the phase 1 program for INV-202 and favorably position the Company to launch later stage clinical trials.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic nephropathy, Non-Alcoholic Steatohepatitis (NASH), complications of obesity, hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF).
Biography and picture available on inversago.com/en/media
– 30 –
Contact:
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma inc.
info@inversago.com
